

**Control Number: 183373**  
**SRN/HIN:**

MYX  
MR SAM SAMPLE  
FLAT 123  
123 SAMPLE STREET  
THE SAMPLE HILL  
SAMPLE ESTATE  
SAMPLEVILLE VIC 3030

27 October 2023

### **2023 Mayne Pharma Group Limited Annual General Meeting**

Dear Fellow Shareholder

On behalf of the Board, I am pleased to invite you to the 2023 Mayne Pharma Group Limited Annual General Meeting (AGM) which will be held at 10.00am (Melbourne time) on Thursday 30<sup>th</sup> November 2023 at MinterEllison Offices, Lvl 20, Collins Arch, 447 Collins St, Melbourne and online at <https://meetnow.global/M2DMXJC>.

The AGM is an important annual event for Mayne Pharma giving shareholders the opportunity to hear from your Chair and your Chief Executive Officer, ask questions about the management and operations of your Company and vote on the items of business.

The Notice of Meeting for the 2023 AGM is available at [maynepharma.com/investor-relations/annual-general-meeting/](https://maynepharma.com/investor-relations/annual-general-meeting/). Shareholders, proxyholders and interested parties can participate in the AGM by attending in person or via the webcast live at <https://meetnow.global/M2DMXJC>. Any shareholders wishing to lodge a proxy vote or lodge questions ahead of the meeting can do this by logging onto <https://www.investorvote.com.au/Login> and entering the Control Number and your holder number (SRN/HIN) located at the top of this letter. Lodging questions or casting your proxy vote ahead of the meeting will not prevent you from attending online or in person. You can also submit questions to [ir@maynepharma.com](mailto:ir@maynepharma.com).

The business of the meeting set out in the Notice of 2023 Annual General Meeting is to:

1. Consider the statutory reports for the financial year ended 30 June 2023;
2. Elect and re-elect your Directors;
3. Adopt the 2023 Remuneration Report;
4. Approve a Short-Term Incentive grant of Restricted Stock Unit Performance Rights and a Long-Term Incentive grant of Performance Rights to the CEO and Managing Director;
5. Approve the appointment of BDO Audit Pty Ltd as the Company's auditor; and
6. Approve the extension of the on-market share buy-back.



**Mayne Pharma Group Limited**  
ABN 76 115 832 963  
[maynepharma.com](https://www.maynepharma.com)

**T** +61 8 8209 2666 **F** +61 8 8281 0284  
1538 Main North Road, Salisbury South, SA 5106 Australia  
PO Box 700, Salisbury, SA 5108 Australia



You deserve tomorrow.

Each Director (where permitted to do so) recommends that shareholders vote in favour of the resolutions in items 2, 3, 4, 5 and 6.

Thank you for your continued support of Mayne Pharma. I hope you can join us for the AGM this year.

Yours sincerely

A handwritten signature in black ink, appearing to read "Frank Condella", written in a cursive style.

Frank Condella  
Chair